Suppr超能文献

髓源抑制细胞和 CCL5 对移植耐受和移植物内调节性 T 细胞定位的控制

Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5.

机构信息

INSERM, Unité Mixte de Recherche en Santé 1064, Nantes F-44093, France;

出版信息

J Immunol. 2012 May 1;188(9):4209-16. doi: 10.4049/jimmunol.1101512. Epub 2012 Mar 26.

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature cells that are believed to inhibit immune responses in the contexts of cancer and organ transplantation, in association with regulatory T cells (Treg). However, the way in which MDSC cooperate with Treg remains elusive. In this study, we used DNA microarrays to analyze gene expression in blood-derived MDSC from rat recipients of kidney allografts. We found CCL5 (Rantes), a chemotactic C-C motif 5 chemokine, to be strongly downregulated after treatment with a tolerizing regimen. The amount of CCL5 protein was also lower in the plasma of tolerant recipients, whereas intragraft CCL5 was unchanged. Because CCL5 is chemotactic for Treg, we hypothesized that a gradient of CCL5 between the graft and peripheral blood might contribute to the intragraft localization of Treg in tolerant animals. To test this hypothesis, we treated tolerant rat recipients of kidney allografts with recombinant rat CCL5 to restore normal plasma concentrations. This led to a strong reduction in intragraft Treg monitored by immunohistofluorescence and by quantitative real-time PCR measurement of Foxp3 mRNA. Ultimately, this treatment led to an increase in serum creatinine concentrations and to kidney graft rejection after about a month. The kidney function of syngeneic grafts was not affected by a similar administration of CCL5. These data highlight the contribution of MDSC to the establishment of a graft-to-periphery CCL5 gradient in tolerant kidney allograft recipients, which controls recruitment of Treg to the graft where they likely contribute to maintaining tolerance.

摘要

髓系来源的抑制细胞(MDSC)是一种异质性不成熟细胞群体,据信与调节性 T 细胞(Treg)一起在癌症和器官移植的背景下抑制免疫反应。然而,MDSC 与 Treg 合作的方式仍不清楚。在这项研究中,我们使用 DNA 微阵列分析了来自接受肾同种异体移植大鼠的血液来源 MDSC 的基因表达。我们发现 CCL5(Rantes),一种趋化性 C-C 基序 5 趋化因子,在用耐受方案治疗后强烈下调。耐受受者血浆中的 CCL5 蛋白量也较低,而移植物内 CCL5 不变。由于 CCL5 对 Treg 具有趋化性,我们假设移植物和外周血之间的 CCL5 梯度可能有助于耐受动物中 Treg 的移植物内定位。为了验证这一假设,我们用重组大鼠 CCL5 处理接受肾同种异体移植的耐受大鼠受者,以恢复正常的血浆浓度。这导致免疫荧光和 Foxp3 mRNA 的定量实时 PCR 测量监测到的移植物内 Treg 数量显著减少。最终,这种治疗导致血清肌酐浓度升高,并在大约一个月后导致肾移植排斥。CCL5 的类似给药对同基因移植物的肾功能没有影响。这些数据突出了 MDSC 在建立耐受肾同种异体移植受者中移植物到外周的 CCL5 梯度中的贡献,该梯度控制 Treg 向移植物的募集,在移植物中它们可能有助于维持耐受。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验